Investors

Press Releases

Press Releases

Date	Title
September 8, 2020	Akebia Therapeutics Announces September 2020 Investor Conference Schedule
September 3, 2020	Akebia Therapeutics Announces Top-Line Results from its PRO2TECT Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients Not on Dialysis
September 2, 2020	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 26, 2020	Akebia Therapeutics Announces First Commercial Launch of VAFSEO™ (vadadustat tablets), a New Oral Treatment for Anemia Due to Chronic Kidney Disease, in Japan
August 10, 2020	Akebia Reports Second Quarter 2020 Financial Results
August 4, 2020	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 3, 2020	Akebia Therapeutics to Report Second Quarter 2020 Financial Results
July 14, 2020	Akebia Announces Initiation of Investigator-Sponsored Study Evaluating Vadadustat for Prevention and Treatment of ARDS in Patients Hospitalized with COVID-19
July 2, 2020	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 29, 2020	Akebia Therapeutics Announces Approval of Vadadustat in Japan for the Treatment of Anemia Due to Chronic Kidney Disease in Dialysis-Dependent and Non-Dialysis Dependent Adult Patients

Print Page

Email Page

Contact IR

Email Alerts

Tear Sheet

Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142

Driving Directions

+1 617.871.2098 phone
+1 617.871.2099 fax